APA (7th ed.) Citation

M, R., A, F., D, V., F, R., KA, H., JS, P., . . . C, S. (2023). Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature communications, 14(1), 7053. https://doi.org/10.1038/s41467-023-42635-2

Chicago Style (17th ed.) Citation

M, Rediti, et al. "Immunological and Clinicopathological Features Predict HER2-positive Breast Cancer Prognosis in the Neoadjuvant NeoALTTO and CALGB 40601 Randomized Trials." Nature Communications 14, no. 1 (2023): 7053. https://doi.org/10.1038/s41467-023-42635-2.

MLA (9th ed.) Citation

M, Rediti, et al. "Immunological and Clinicopathological Features Predict HER2-positive Breast Cancer Prognosis in the Neoadjuvant NeoALTTO and CALGB 40601 Randomized Trials." Nature Communications, vol. 14, no. 1, 2023, p. 7053, https://doi.org/10.1038/s41467-023-42635-2.